FerroChel® (Ferrous Bisglycinate Chelate)

Evidence Level
Strong
3 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

FerroChel® (Albion Minerals, now part of Balchem) is the patented ferrous bisglycinate chelate — an iron salt in which each Fe²⁺ ion is chelated to two glycine molecules forming a stable, electrically neutral complex. Compared with conventional ferrous sulfate, FerroChel® shows several-fold higher absorption in some food matrices, is less affected by phytates and polyphenols, and consistently produces fewer gastrointestinal complaints (constipation, nausea, dark stool, metallic taste). The chelated structure protects the iron through the upper GI tract, supporting both bioavailability and tolerability for use in routine iron supplementation and food fortification.

Studied Dose Typical FerroChel® doses provide 14–28 mg elemental iron once daily for routine repletion; pediatric and pregnancy doses use 5–28 mg/day depending on indication. Trials in iron-deficient women and food fortification work commonly use 14–30 mg elemental iron/day.
Active Compound Ferrous bisglycinate chelate (Fe²⁺ chelated to two glycine ligands) — FerroChel® by Albion Minerals / Balchem; typical iron content 18–20% by weight

Benefits

Higher bioavailability than ferrous sulfate

Stable isotope and clinical absorption studies show ferrous bisglycinate is absorbed several-fold more efficiently than ferrous sulfate in many food matrices, particularly those high in phytates and polyphenols, supporting more efficient hemoglobin response per milligram of elemental iron.

Improved gastrointestinal tolerability

Compared with ferrous sulfate at equivalent elemental iron, FerroChel® has been associated with fewer reports of nausea, constipation, metallic taste, dark stool, and abdominal discomfort. Better tolerability supports adherence over the months typically required for iron repletion.

Effective correction of iron deficiency anemia

Clinical trials in anemic women and young children have demonstrated meaningful hemoglobin and ferritin improvements with ferrous bisglycinate at typical supplemental doses, supporting use for correction of iron deficiency anemia and prevention of recurrence.

Robust absorption in plant-based diets

Because chelation protects the iron from binding inhibitors such as phytates and tannins, FerroChel® is particularly relevant for vegetarian, vegan, and high-fiber dietary patterns where non-heme iron absorption from food is otherwise low.

Mechanism of action

1

Chelated structure protects iron through the GI tract

The two glycine ligands surround the Fe²⁺ ion, forming a stable, electrically neutral chelate that resists binding to dietary phytates, polyphenols, and other absorption inhibitors. The intact chelate is transported into enterocytes via amino acid and peptide pathways, after which the iron is released for normal use.

2

Less generation of free radical iron in the gut lumen

Conventional iron salts liberate free Fe²⁺ in the gut lumen, which can catalyze Fenton-type reactions, irritate the mucosa, and contribute to GI side effects. The chelated form of FerroChel® reduces free luminal iron, plausibly explaining the improved tolerability profile.

3

Use of amino acid transporters rather than DMT1 alone

Beyond classical DMT1-mediated non-heme iron uptake, the bisglycinate chelate appears to enter enterocytes partly via amino acid and dipeptide transporters. This alternative uptake pathway helps explain higher absorption rates that are less dependent on competing dietary minerals.

4

Regulated absorption by body iron status

Like other non-heme iron forms, ferrous bisglycinate absorption is downregulated by hepcidin when body iron stores are adequate and upregulated in iron deficiency. This natural feedback reduces (but does not eliminate) the risk of iron overload at therapeutic supplemental doses.

Clinical trials

1
Ferrous Bisglycinate Absorption in Maize Meals

Stable isotope iron absorption study comparing ferrous bisglycinate and ferric trisglycinate fortification of maize meals against ferrous sulfate in adults with varying iron status. Published in American Journal of Clinical Nutrition.

Adults with a range of iron stores; controlled meal-based absorption study.

Ferrous bisglycinate absorption from whole maize was several-fold higher than ferrous sulfate at equivalent iron doses, and absorption was inversely related to body iron status — consistent with normal regulatory control while delivering meaningfully more iron per milligram of fortificant.

2
Iron Bisglycinate vs Ferrous Sulfate in Iron-Deficiency Anemia in Children

Randomized comparative trial of ferrous bisglycinate versus ferrous sulfate for treatment of iron deficiency anemia in infants and young children. Outcomes: hemoglobin response, GI tolerability.

Infants and young children with iron deficiency anemia.

Ferrous bisglycinate produced effective hemoglobin recovery with notably higher relative bioavailability than ferrous sulfate, supporting clinical use of bisglycinate for pediatric iron repletion with comparable or improved tolerability.

3
Iron Bioavailability from Phytate-Containing Foods

Human iron absorption study evaluating bioavailability of iron bisglycinate compared with ferrous sulfate in breakfasts enriched with phytate and polyphenol-rich foods. Published in European Journal of Clinical Nutrition.

Adult volunteers; controlled meal-based absorption study.

Iron bisglycinate absorption was substantially less impaired by phytates and polyphenols than ferrous sulfate. The bisglycinate form preserved meaningful absorption in inhibitor-rich meals, supporting its use in plant-based and high-fiber dietary patterns where non-heme iron absorption is otherwise low.

Side effects and drug interactions

Common Potential side effects

Generally better tolerated than ferrous sulfate but still possible: mild constipation or nausea.
Dark stools — a normal pharmacologic effect, not a safety concern.
Stomach upset if taken on an empty stomach; consider taking with food.
Risk of iron overload with chronic excess intake; avoid combining iron supplements without monitoring.
Accidental overdose in children is a serious medical emergency — store securely.

Important Drug interactions

Levothyroxine — iron reduces thyroid hormone absorption; separate dosing by at least 4 hours.
Tetracycline and fluoroquinolone antibiotics — iron forms insoluble complexes; separate by 2–4 hours.
Bisphosphonates — iron impairs absorption; separate dosing by several hours.
Proton pump inhibitors and antacids — reduced gastric acidity may decrease iron absorption.

Frequently asked questions about FerroChel® (Ferrous Bisglycinate Chelate)

What is the recommended dosage of FerroChel® (Ferrous Bisglycinate Chelate)?

The clinically studied dose for FerroChel® (Ferrous Bisglycinate Chelate) is Typical FerroChel® doses provide 14–28 mg elemental iron once daily for routine repletion; pediatric and pregnancy doses use 5–28 mg/day depending on indication. Trials in iron-deficient women and food fortification work commonly use 14–30 mg elemental iron/day.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is FerroChel® (Ferrous Bisglycinate Chelate) used for?

FerroChel® (Ferrous Bisglycinate Chelate) is studied for higher bioavailability than ferrous sulfate, improved gastrointestinal tolerability, effective correction of iron deficiency anemia. Stable isotope and clinical absorption studies show ferrous bisglycinate is absorbed several-fold more efficiently than ferrous sulfate in many food matrices, particularly those high in phytates and polyphenols, supporting more efficient hemoglobin r…

Are there side effects from taking FerroChel® (Ferrous Bisglycinate Chelate)?

Reported potential side effects may include: Generally better tolerated than ferrous sulfate but still possible: mild constipation or nausea. Dark stools — a normal pharmacologic effect, not a safety concern. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does FerroChel® (Ferrous Bisglycinate Chelate) interact with medications?

Known drug interactions may include: Levothyroxine — iron reduces thyroid hormone absorption; separate dosing by at least 4 hours. Tetracycline and fluoroquinolone antibiotics — iron forms insoluble complexes; separate by 2–4 hours. Consult a pharmacist or healthcare provider if you take prescription medications.

Is FerroChel® (Ferrous Bisglycinate Chelate) good for women's health?

Yes, FerroChel® (Ferrous Bisglycinate Chelate) is researched for Women's Health support. Stable isotope and clinical absorption studies show ferrous bisglycinate is absorbed several-fold more efficiently than ferrous sulfate in many food matrices, particularly those high in phytates and polyphenols, supporting more efficient hemoglobin response per milligram of eleme…

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Bovell-Benjamin AC, Viteri FE, Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr. 2000;71(6):1563-9. doi: 10.1093/ajcn/71.6.1563.PubMedUsed to support: Stable isotope absorption study — ferrous bisglycinate absorption from maize meals was several-fold higher than ferrous sulfate, with absorption inversely related to body iron status (normal feedback), supporting FerroChel®-grade bioavailability.
  2. Layrisse M, García-Casal MN, Solano L, Barón MA, Arguello F, Llovera D, Ramírez J, Leets I, Tropper E. Iron bioavailability in humans from breakfasts enriched with iron bis-glycine chelate, phytates and polyphenols. J Nutr. 2000;130(9):2195-9. doi: 10.1093/jn/130.9.2195.PubMedUsed to support: Human absorption study — iron bisglycinate maintained meaningfully better absorption than ferrous sulfate in breakfasts rich in phytates and polyphenols, supporting its use in plant-based and inhibitor-rich diets.
  3. Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381-4. doi: 10.1016/s0899-9007(01)00519-6.PubMedUsed to support: Comparative trial in infants and young children with iron-deficiency anemia — ferrous bisglycinate chelate showed substantially higher relative bioavailability (reported ~90% vs ~27%) than ferrous sulfate with effective hemoglobin recovery.